Chronic Inflammatory Demyelinating Polyneuropathy Market Poised for Steady Expansion Through 2035 – BIS Research

What is CIDP? 

Chronic inflammatory demyelinating polyneuropathy is a rare, immune-mediated neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms. The condition results from damage to the myelin sheath of peripheral nerves and may present in relapsing, progressive, or monophasic forms. Without treatment, CIDP can cause significant disability, but timely immunomodulatory therapy can improve long-term outcomes. 

What Is the Market Outlook? 

Technology Growth: 

The treatment paradigm is evolving from reliance solely on plasma-derived IVIG to more personalized regimens, including SCIG for home-based therapy, novel FcRn inhibitors, and monoclonal antibodies targeting immune pathways. 

Regional Drivers: 

• North America: Strongest market presence, driven by high diagnosis rates, established plasma collection networks, and favorable insurance coverage. 
• Europe: Demand supported by orphan drug policies, cross-border healthcare initiatives, and strong adoption of SCIG. 
• Asia-Pacific: Rapidly expanding plasma fractionation facilities, improving access to neurology specialists, and greater participation in global CIDP trials. 

Commercialization Push: 

Strategic alliances between plasma therapy manufacturers and biotech firms are accelerating the introduction of next-generation CIDP therapies in both mature and emerging markets. 

How Fast Is the Market Growing? 

The CIDP market is expected to grow steadily through 2035, with immunoglobulin-based therapies maintaining the largest revenue share. However, targeted biologics and oral immunomodulators are forecast to outpace traditional therapies in growth rate as late-stage clinical trials mature. 

How Will This Report Help You? 

Planning to Enter the Market? 

Gain insights into patient treatment preferences, access limitations, and physician prescribing patterns across regions. 

Analyzing the Competitive Landscape? 

Review clinical development pipelines, biosimilar IVIG entries, and patent expirations affecting therapy pricing and adoption. 

Seeking R&D Insights? 

Track ongoing trials of FcRn inhibitors, complement inhibitors, and B-cell–depleting agents in CIDP. 

Interested in Regional Market Trends? 

Assess country-specific reimbursement schemes, plasma collection capacities, and neurology network density. 

Download the Full TOC or Book a Preview     

What’s Driving Demand, Opportunities, and Barriers? 

Demand Drivers: 

• Rising CIDP awareness among general practitioners and neurologists 
• Expansion of plasma collection centers to support IVIG supply 
• Introduction of SCIG enabling flexible, home-based treatment 

Opportunities: 

• Geographic expansion of novel biologics into Asia-Pacific and Latin America 
• Development of biomarker-based patient stratification tools 
• Partnerships to scale SCIG delivery infrastructure 

Challenges: 

• High per-patient therapy cost due to chronic treatment needs 
• Risk of supply bottlenecks in plasma-derived products 
• Variable diagnosis rates in low-resource settings 

Market Segmentation: 

by Distribution Channel 

• Hospital Pharmacy 

• Retail Pharmacy 

• Online Pharmacy 

by Route of Administration 

• Intravenous 

• Oral 

• Others 

by Region 

• North America 

• Europe  

• Asia-Pacific 

• Rest of the World 

Strategic Developments: 

• New clinical trial starts for FcRn inhibitors and anti-complement therapies in CIDP 
• Expansion of global plasma collection networks to meet growing IVIG demand 
• Regulatory approvals of SCIG formulations for CIDP in multiple geographies 

Download the complete TOC now! 

Case Study: 

Recent trials of FcRn inhibitors have demonstrated promising reductions in disease activity and steroid dependence in CIDP patients, highlighting the potential to diversify beyond immunoglobulin-based treatments. 

Schedule a Call with Industry Experts  

Related Reports from BIS Research  

Inflammatory Bowel Disease Treatment Market 

Flow Cytometry Market 

Stuttering Market 

About BIS Research  

BIS Research is a global B2B market intelligence and advisory firm focusing on deep technology and related emerging trends, which can disrupt the market dynamics in the near future. We publish over 200 market intelligence studies annually, focusing on several deep technology verticals.    

Our strategic market analysis emphasizes market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.     

BIS Research offers syndicate and custom studies and expert consultations to firms, providing them with specific and actionable insights on novel technology markets, business models, and competitive landscapes.    

Contact  

Head of Marketing   

Email: media@bisresearch.com     

BIS Research Inc.    

39111 PASEO PADRE PKWY STE 313,    

FREMONT, CA 94538-1686   

Visit our Blog @https://bisresearch.com/insights    

Get Expert Insights @https://community.insightmonk.com     

Connect with us on LinkedIn @ https://www.linkedin.com/company/bis-research     

Connect with us on Twitter@ https://twitter.com/BISResearch    

Connect with us on Medium@ https://medium.com/@faisal.bis  

Connect with us on youtube@ https://www.youtube.com/@BISResearchInc